$MVTG .20 News Mantra Energy Alternatives Reports Major

New Post Public Reply Private Reply Replies (0) Message Board
jstops

[b]$MVTG[/b] .20 News Mantra Energy Alternatives Reports Major Technology Development Progress, Taking It One Step Closer to Pilot Plant

SEATTLE, WASHINGTON, Oct 25, 2012 (MARKETWIRE via COMTEX) -- Mantra Venture Group Ltd. (OTCBB: MVTG)(FRANKFURT: 5MV) today announced that its Mantra Energy Alternatives Ltd. subsidiary has achieved significant progress in key elements of its technology development contract with Powertech, with the primary near term goal of an ERC pilot facility.

Mantra's ERC process aims to capture CO2 from industrial activities, such as cement production, and convert it to marketable chemicals including formate salts or formic acid.

Some of the highlights of the technology development to date include:

--  Powertech has completed the initial design of the CO2 enrichment process

based on stack gas data from the pilot facility site. We have since

built and tested a bench scale unit which proves the capability to

concentrate CO2 from 20% (in the original stack gas) to 80%. When scaled

up to size this achievement will allow for a feed concentration of 80%

CO2 to the ERC pilot plant.

--  In a re-design led by Powertech, the ERC cell anode's capabilities have

been markedly improved which will allow heightened performance

repeatability

--  Mantra has successfully demonstrated performance comparable to ERC

electrodes using an alternate GDE-type electrode design. Using this as a

baseline, Mantra will now begin a comprehensive material screening

process to continue the improvement of catalyst lifetimes and overall

process performance and efficiency. This approach is a significant event

for Mantra as it provides the Company with the flexibility to utilize

more dilute CO2 streams such as those from biomass energy conversion

projects. It will also allow for the flexibility of going straight to

formic acid without the formate step.

"We are pleased with the tremendous progress we have made on our technology development in just a few short months," stated Neil Huff, COO of Mantra Energy. "The CO2 enrichment and cell improvements made by Powertech take us one step closer to the completion of our pilot facility. The parallel approach using the GDE design will give Mantra additional flexibility and help create further opportunities in the CCU space."

About Mantra Energy Alternatives:

Mantra Energy Alternatives Ltd. is a wholly owned subsidiary of Mantra Venture Group Ltd. Its mission is to become the world leader in production of high value, carbon negative chemicals and fuels. Mantra's ERC system will reduce the problem greenhouse gas CO2 and convert it into a series of valuable chemicals, a form of carbon capture and recycling (CCR). There are currently 27 billion metric tons of CO2 emitted annually from fossil fuel combustion, providing an inexhaustible supply of feedstock. The first product is formic acid (HCOOH), which commands a market of approximately USD $1 billion.

Mantra is a public company quoted on the OTC BB under the symbol MVTG and on the Frankfurt Stock Exchange under the symbol 5MV.

Stay up to date with Mantra on Twitter: http://www.twitter.com/mantraenergy

For more information go to: http://www.mantraenergy.com

About Powertech Labs:

Powertech Labs Inc. is a wholly owned subsidiary of BC Hydro, one of the largest electric utilities in Canada. Powertech is a multidisciplinary research and testing facility that specializes in clean energy consulting, independent testing and power system solutions. Since its inception in 1979, Powertech has served electrical power utilities, electrical and automotive equipment manufacturers, and oil and gas companies from around the world.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 188

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 384

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 260

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 267

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 392

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 382

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 371

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 472

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 344

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 433

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
/news?page=2">More News Articles